Table 1 Multivariate survival analysis results of the ten snRNAs included in the risk score model in AML.

From: Expression signature of ten small nuclear RNAs serves as novel biomarker for prognosis prediction of acute myeloid leukemia

ID

Ensemble ID

Adjusted P§

HR

Low 95%CI

High 95%CI

RNU6-1143P

ENSG00000251934

0.000272814

0.426713992

0.269758037

0.674993163

RNU6-1272P

ENSG00000199646

0.001142804

0.451039966

0.279165911

0.728731709

RNU6-202P

ENSG00000251807

0.001349364

0.468147755

0.294325617

0.744625366

RNU6-1274P

ENSG00000207287

0.002548141

2.026689935

1.280923906

3.206648007

U1

ENSG00000278099

0.003877337

1.955643381

1.240514241

3.083028722

RNU6ATAC39P

ENSG00000252118

0.005643496

1.903128765

1.206614834

3.001702776

RNU6-761P

ENSG00000206875

0.008652609

1.861213512

1.170547774

2.959397141

RNU4-8P

ENSG00000201806

0.008699737

1.848034

1.168063504

2.923839031

RNU6-110P

ENSG00000207237

0.00908825

0.542894557

0.343086512

0.859067581

RNU6-946P

ENSG00000206605

0.009464659

0.539917887

0.338955868

0.860027371

  1. AML acute myeloid leukemia, snRNA small nuclear RNA, FAB French-American-British, HR hazard ratio, CI confidence interval.
  2. §Adjusted for age and FAB morphology type in multivariate Cox proportional hazards regression model.
Back to article page